anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: BECLOMETHASONE DIPROPIONATE
Trial phase: Phase 3
ATC code: A07EA07 | D07AC15 | D07CC04 | R01AD01 | R03AK08 | R03AK13 | R03AL09 | R03BA01
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 715
Group description: Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
Eligibility criteria:
Inclusion Criteria:

Male or female subjects 6 to 11 years of age, as of the Screening Visit (SV)
A documented history of SAR to a relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV).
A demonstrated sensitivity to at least one seasonal allergen (tree/grass pollen) known to induce SAR through a standard skin prick test.
Other criteria apply

Exclusion Criteria:

History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit [SV])
History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza,) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.
Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable
Have any conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial
Other criteria apply
Intervention: Anidulafungin
Trial phase: Phase 4
ATC code: J02AX06
SMILES: [H][C@@]1([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)c2ccc(-c3ccc(-c4ccc(OCCCCC)cc4)cc3)cc2)C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.

Anidulafungin: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
Eligibility criteria:
Inclusion Criteria:

Male and female subjects, age > 18 years old, of all racial and ethnic origins.
Non-English-speaking Spanish speakers will be included in the study.
The investigators are recruiting six normal or underweight (BMI < 25 kg/m2), six overweight or obese (BMI 25-40 kg/m2), and six extremely obese (BMI > 40 kg/m2) for this study. This index is calculated using the volunteer's height and weight (Formula: weight (lb) / [height (in)]2 x 703). Half of each group will be male; the other half will be female.

Exclusion Criteria:

Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of anidulafungin on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of anidulafungin, so that the pregnancy and postpartum state would be a confounding variable.
Abnormal liver function tests: transaminases > 3 times upper limit of normal, Alkaline phosphatase > 3 times upper limit of normal, total bilirubin > 3 times upper limit of normal.
History of allergies to echinocandins.
Echinocandins are contraindicated for any reason.
Volunteers unwilling to comply with study procedures.
Suspected or documented systemic fungal infection.
Concomitant use of rifamycins, tacrolimus, or cyclosporine.
Current participation or previous participation within 28 days of enrollment in another research study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance) (Unless waved by PI).
Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study enrollment (Unless waved by PI).
Creatinine Clearance < 70 ml/min as estimated by the Cockcroft-Gault equation.
Intervention: Desflurane
Trial phase: Phase 4
ATC code: N01AB07
SMILES: FC(F)OC(F)C(F)(F)F
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 57
Group description: During the surgery the subjects will be given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form is inhalation gas, dosage equivalent to 1 MAC, frequency is once and the duration is throughout the surgery (30-45 minutes).
Eligibility criteria:
Inclusion Criteria:

> 65 years old, female subjects
Scheduled for brief urologic surgery (Cyctoscopy, Ureteral stent, Laserlithotripsy, Ureteroscopy, Vaginal sling, Bladder injury repair, Rectocele repair and Stone extraction)
Ability to read, write and speak English language
Driving at least one year

Exclusion Criteria:

Preexisting neurological impairment in thinking process
Renal insufficiency or failure
Lack of command of English language
Inability to drive
Motion Sickness
Intervention: Sevoflurane
Trial phase: Phase 4
ATC code: N01AB08
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 57
Group description: During the surgery the subjects will be given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form is inhalation gas, dosage equivalent to 1 MAC, frequency is once and the duration is throughout the surgery (30-45 minutes).
Eligibility criteria:
Inclusion Criteria:

> 65 years old, female subjects
Scheduled for brief urologic surgery (Cyctoscopy, Ureteral stent, Laserlithotripsy, Ureteroscopy, Vaginal sling, Bladder injury repair, Rectocele repair and Stone extraction)
Ability to read, write and speak English language
Driving at least one year

Exclusion Criteria:

Preexisting neurological impairment in thinking process
Renal insufficiency or failure
Lack of command of English language
Inability to drive
Motion Sickness
Intervention: Brinzolamide
Trial phase: Phase 3
ATC code: G01AE10 | S01EC04 | S01EC54
SMILES: CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 192
Group description: Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
Eligibility criteria:
Inclusion Criteria:

Diagnosed with open angle glaucoma or ocular hypertension, and, in the opinion of the Investigator, are insufficiently controlled on monotherapy or are currently on multiple IOP-lowering medications.
Meet qualifying IOP entry criteria.
Able to understand and sign an informed consent form.
Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

Women of childbearing potential if pregnant, test positive for pregnancy at Screening Visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
Severe central visual field loss.
Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen equivalent).
Chronic, recurrent or severe inflammatory eye disease.
Ocular trauma within the preceding 6 months.
Ocular infection or ocular inflammation within the preceding 3 months.
Clinically significant or progressive retinal disease.
Other ocular pathology.
Intraocular surgery within the 6 months prior to entry.
Ocular laser surgery within the 3 months prior to entry.
Any abnormality preventing reliable applanation tonometry.
Any other conditions, including severe illness, which would make the subject, in the opinion of the Investigator, unsuitable for the study.
Recent use of high-dose (>1 gram daily) salicylate therapy.
Recent, current, or anticipated treatment with any medication that augments adrenergic responses, or precludes use of an alpha-adrenergic agonist.
Concurrent use of glucocorticoid medications administered by any route.
Other protocol-specified exclusion crtieria may apply.
Intervention: Brimonidine Tartrate
Trial phase: Phase 3
SMILES: Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 175
Group description: Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
Eligibility criteria:
Inclusion Criteria:

Diagnosed with open angle glaucoma or ocular hypertension, and, in the opinion of the Investigator, are insufficiently controlled on monotherapy or are currently on multiple IOP-lowering medications.
Meet qualifying IOP entry criteria.
Able to understand and sign an informed consent form.
Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

Women of childbearing potential if pregnant, test positive for pregnancy at Screening Visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
Severe central visual field loss.
Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen equivalent).
Chronic, recurrent or severe inflammatory eye disease.
Ocular trauma within the preceding 6 months.
Ocular infection or ocular inflammation within the preceding 3 months.
Clinically significant or progressive retinal disease.
Other ocular pathology.
Intraocular surgery within the 6 months prior to entry.
Ocular laser surgery within the 3 months prior to entry.
Any abnormality preventing reliable applanation tonometry.
Any other conditions, including severe illness, which would make the subject, in the opinion of the Investigator, unsuitable for the study.
Recent use of high-dose (>1 gram daily) salicylate therapy.
Recent, current, or anticipated treatment with any medication that augments adrenergic responses, or precludes use of an alpha-adrenergic agonist.
Concurrent use of glucocorticoid medications administered by any route.
Other protocol-specified exclusion crtieria may apply.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: Normal Saline : 1.33cc of normal saline
Eligibility criteria:
Inclusion Criteria:

Women eligible for IUD insertion
Willing to give consent

Exclusion Criteria:

Allergy to lidocaine
Contraindications to IUD use
Intervention: Simethicone
Trial phase: Phase 2
SMILES: CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 125 mg tablet

Simethicone: single 125 mg chewable tablet
Eligibility criteria:
Inclusion Criteria:

Age 18 to 50 years
Healthy subjects other than current upper respiratory tract infection ("cold")
Jackson Score of 6 on screening
Subject reports symptom onset within 4 days of entry visit
Unilateral or bilateral middle-ear pressure <-50 mmH2O

Exclusion Criteria:

Otoscopic diagnosis of unilateral or bilateral otitis media
Presence of tympanostomy tubes or tympanic membrane perforations bilaterally
Asthma or any chronic medical disease or condition
Use of an "over the counter" medicine within 24 hours of study or prescription within 4 weeks of the study day (except birth control)
Use of an experimental drug within 3 months of study
An unusual or allergic reaction to simethicone, food dyes, or preservatives
Pregnancy or breast feeding
Ear surgery other than tympanostomy tube insertion
Intervention: OXYTOCIN
Trial phase: Not Applicable
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Male
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.

Oxytocin: Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
Eligibility criteria:
Inclusion Criteria:

Veteran being treated in the Veterans Administration Healthcare System
Meet DSM-IV-TR criteria for Schizophrenia
At least 6 months since any hospitalization or substantial increase in level of care for an acute exacerbation of psychotic symptoms
At least 1 month since meeting the criteria for having a major depressive episode
At least 6 months since any behaviors suggesting any potential danger to self or others
Adherence to the regular administration of an antipsychotic medication (e.g., risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, iloperidone, asenapine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, thiothixene, chlorpromazine, clozapine)
Dose of antipsychotic medication not varying by more than 25% over the 3 months prior to study participation
No acute medical problems
Chronic medical conditions (e.g., hypertension, diabetes, dyslipidemia) consistently treated and stable for at least 3 months prior to study participation
Ability to provide signed informed consent and to cooperate with study procedures

Exclusion Criteria:

Documented history of mental retardation or severe learning disability
History of treatment with electroconvulsive therapy within 6 months prior to study participation
History of neurological or neuropsychiatric condition (e.g., stroke, severe traumatic brain injury, epilepsy, etc.)
Documented history of persistent substance abuse or dependence within 6 months prior to study participation
History of hyponatremia within the past 6 months
Allergic rhinitis or other inflammation of the nasal mucosa
Intervention: Human Menopausal Gonadotrophin
Trial phase: Phase 3
ATC code: G03GA02
SMILES: CC(C)(C)CCCCC=O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 135
Group description: New hMG preparation.

Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
Eligibility criteria:
Inclusion Criteria:

Women undergoing ovarian stimulation for IVF with the following characteristics:

Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule
>18 and <40 years old
BMI between 18 and 30 kg/m2
less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery)
basal FSH <10 IU/L and E2 <80 pg/ml (~290 pmol/l)
Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination
Successful down-regulation performed with a standard GnRH-Agonist long protocol (Criteria for successful down-regulation: endometrial thickness < 7mm or serum E2 level <50 pg/ml (~185 pmol/l).

Exclusion Criteria:

age <18 and >40 years
primary ovarian failure or women known as poor responders (i.e. requiring more than 225 IU of hMG as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a pre-ovulatory E2 serum concentration <500pg/ml (~1800 pmol/l))
PCOS
one or both ovaries inaccessible for oocyte retrieval
ovarian cysts >10 mm
hydrosalpinx that have not been surgically removed or ligated;
stage 3 or 4 endometriosis
oocyte donation
implantation of previously frozen embryos
patients affected by pathologies associated with any contraindication of being pregnant
hypersensitivity to the study medication
abnormal bleeding of undetermined origin
uncontrolled thyroid or adrenal dysfunction
neoplasias
severe impairment of renal and/or hepatic function
use of concomitant medications that might interfere with study evaluations (e.g. non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)
Intervention: Human Menopausal Gonadotrophin
Trial phase: Phase 3
ATC code: G03GA02
SMILES: CC(C)(C)CCCCC=O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 135
Group description: Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
Eligibility criteria:
Inclusion Criteria:

Women undergoing ovarian stimulation for IVF with the following characteristics:

Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule
>18 and <40 years old
BMI between 18 and 30 kg/m2
less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery)
basal FSH <10 IU/L and E2 <80 pg/ml (~290 pmol/l)
Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination
Successful down-regulation performed with a standard GnRH-Agonist long protocol (Criteria for successful down-regulation: endometrial thickness < 7mm or serum E2 level <50 pg/ml (~185 pmol/l).

Exclusion Criteria:

age <18 and >40 years
primary ovarian failure or women known as poor responders (i.e. requiring more than 225 IU of hMG as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a pre-ovulatory E2 serum concentration <500pg/ml (~1800 pmol/l))
PCOS
one or both ovaries inaccessible for oocyte retrieval
ovarian cysts >10 mm
hydrosalpinx that have not been surgically removed or ligated;
stage 3 or 4 endometriosis
oocyte donation
implantation of previously frozen embryos
patients affected by pathologies associated with any contraindication of being pregnant
hypersensitivity to the study medication
abnormal bleeding of undetermined origin
uncontrolled thyroid or adrenal dysfunction
neoplasias
severe impairment of renal and/or hepatic function
use of concomitant medications that might interfere with study evaluations (e.g. non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)
Intervention: Scopolamine
Trial phase: Phase 2
ATC code: A04AD01 | A04AD51 | N05CM05 | S01FA02
SMILES: CN1C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Patients receiving IV scopolamine at ECT treatment

Scopolamine: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Eligibility criteria:
Inclusion Criteria:

Males and females between the ages of 18-50 (inclusive)
DSM-IV diagnosis of Major Depressive Disorder (MDD), without psychotic features, and a HAM-D-17 score of 18 or higher
Female subjects must be postmenopausal, surgically sterile, or, if of child-bearing age, using double-barrier contraceptive method or prescription oral contraceptives (e.g. estrogen-progestin combinations), contraceptive implants (e.g. NorplantTM, DepoProveraTM, or transdermally delivered contraceptives (Ortho EvraTM) before entry and throughout the study; and have a negative urine b-HCG pregnancy test at screening.

Exclusion Criteria:

Substance use disorder active use within the last 6 months (per assessment using SCID)
Organic mental disorders
Seizure disorders
Unstable physical disorder or physical disorder judged to significantly affect the central nervous system function
Heart block
Pre-existing sick-sinus
Chronic treatment with beta blockers
Any cardiac arrhythmia
Hypotension
Coronary artery disease
Liver and renal function impairment
Urge incontinence or prostatic hypertrophy
Colitis
Crohn's disease
GI motility disorders
Asthma
COPD
Treatment with anti-cholinergic and cholinomimetic medications
Contraindications to scopolamine including hypersensitivity to scopolamine, other belladonna alkaloids, and/or any component of the formulation
Wide and narrow angle glaucoma
Acute hemorrhage
Paralytic ileus
Myasthenia gravis
Patients on belladonna, belladonna alkaloids, cisapride, or potassium chloride
Intervention: Scopolamine
Trial phase: Phase 2
ATC code: A04AD01 | A04AD51 | N05CM05 | S01FA02
SMILES: CN1C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Patients receiving IV placebo at ECT treatment

Scopolamine: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Eligibility criteria:
Inclusion Criteria:

Males and females between the ages of 18-50 (inclusive)
DSM-IV diagnosis of Major Depressive Disorder (MDD), without psychotic features, and a HAM-D-17 score of 18 or higher
Female subjects must be postmenopausal, surgically sterile, or, if of child-bearing age, using double-barrier contraceptive method or prescription oral contraceptives (e.g. estrogen-progestin combinations), contraceptive implants (e.g. NorplantTM, DepoProveraTM, or transdermally delivered contraceptives (Ortho EvraTM) before entry and throughout the study; and have a negative urine b-HCG pregnancy test at screening.

Exclusion Criteria:

Substance use disorder active use within the last 6 months (per assessment using SCID)
Organic mental disorders
Seizure disorders
Unstable physical disorder or physical disorder judged to significantly affect the central nervous system function
Heart block
Pre-existing sick-sinus
Chronic treatment with beta blockers
Any cardiac arrhythmia
Hypotension
Coronary artery disease
Liver and renal function impairment
Urge incontinence or prostatic hypertrophy
Colitis
Crohn's disease
GI motility disorders
Asthma
COPD
Treatment with anti-cholinergic and cholinomimetic medications
Contraindications to scopolamine including hypersensitivity to scopolamine, other belladonna alkaloids, and/or any component of the formulation
Wide and narrow angle glaucoma
Acute hemorrhage
Paralytic ileus
Myasthenia gravis
Patients on belladonna, belladonna alkaloids, cisapride, or potassium chloride
Intervention: Selumetinib
Trial phase: Early Phase 1
ATC code: L01EE04
SMILES: Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
Eligibility criteria:
Inclusion Criteria:

Female breast cancer patient > 18 years.
Patients must have biopsy-proven clinical Stage Ic-III invasive breast carcinoma with ≤ 10% ER expression by immunohistochemistry (IHC) analysis.
Patients must have a pre-treatment baseline core biopsy or incisional biopsy available for additional testing (ER, protein/gene expression analysis).
Patients must have sufficient tumor remaining following diagnostic biopsy that requires an additional definitive surgical procedure per the standard of care. Planned procedure may include lumpectomy or mastectomy as clinically indicated.
Patients must have an ECOG Performance Status of 0 - 1.
Patients must have the ability to understand and willingness to sign an English or a Spanish language written informed consent document.

Exclusion Criteria:

Male breast cancer patient.
Patients who are pregnant or breast-feeding are excluded from the study due to potential harm to the fetus or nursing infant from the study therapy. Patients of reproductive potential must consent to use of contraception or abstinence to be eligible for the study.
Patients may not have received prior chemotherapy or hormonal therapy for treatment of the current breast cancer.
Patients should not have known or strongly suspected BRCA mutation by history (genetic testing not required).
Patients will have pre-study testing, including history and physical exam, complete blood count, and measurement of renal and hepatic function. Patients will be ineligible for the study if significant abnormalities are detected, in accordance with good medical practice.